Itonis Pharmaceuticals Provides Updates on Emesyl® Manufacturing and Case Study

Posted 11:23:00 03/11/2016 by Admin


LAGUNA HILLS, CA -- March 11, 2016 -- InvestorsHub NewsWire -- Itonis, Inc. (OTC Pinksheets: ITNS) is pleased to provide this update regarding its manufacturing of its Emesyl homeopathic nausea relief product and regarding a case study on Emesyl.

The Company previously announced that it had narrowed its selection of a new manufacturer to replace Oasis Health Products for the production of Emesyl. After a considerable process of comparing and assessing manufacturing capabilities and scheduling deliverables in alignment with the Companys goals, there will soon be an announcement identifying the new manufacturer along with details of the first production order.

The Company had also commissioned a case study of Emesyl. That case study has recently been completed, and the results are being compiled for presentation and delivery to the Company for a subsequent announcement and publication.

Meanwhile, Emesyl is available for purchase at http://www.Emesyl.com.

While it has been a time-consuming process, we are delighted that we can move forward with a new manufacturer and eventually renew our efforts to market and sell Emesyl, says Mark Cheung, the Companys CEO. Concurrently we had also commissioned the case study, now and it looks like we are achieving both the manufacturing re-start and the case study completion at the same time.

As the inventor of Emesyl, I am especially pleased at the company's recent progress towards renewing the production of the product, said Dr. Charles Hensley. He added, I look forward to participating in the growth and development of this amazing product as it moves towards becoming a staple in every American household.



About Itonis Pharmaceuticals

Itonis Pharmaceuticals, a division of Itonis, Inc., is headed by Charles Hensley, Ph.D., and its mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.

About Itonis, Inc.

Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com.

Safe Harbor:

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

Contact:

Itonis, Inc.

Office@itonisholdings.com


http://ih.advfn.com/p.php?pid=nmona&article=70736111



 

Stock Quote - ITNS

ITNS Last:  $0.0012 Change:  --

Investor Relations

Itonis Holdings Company is a trade name of Itonis Inc. (OTC:ITNS), a publicly traded company.



Contact our office at (949) 200-8887 or email us at office@itonisholdings.com for more information.